GALT - Galectin Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Galectin Therapeutics, Inc.

4960 Peachtree Industrial Boulevard
Suite 240
Norcross, GA 30071
United States
678-620-3186
http://www.galectintherapeutics.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees7

Key Executives

NameTitlePayExercisedAge
Dr. Peter G. Traber M.D.733.94kN/A62
Mr. Jack W. Callicutt CPA363.27kN/A50
Dr. Harold H. Shlevin Ph.D.359.04kN/A67
Robert TrittN/AN/AN/A
Dr. Eliezer Zomer Ph.D.N/AN/A70
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company’s lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.

Corporate Governance

Galectin Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.